Detalhe da pesquisa
1.
Reducing affinity as a strategy to boost immunomodulatory antibody agonism.
Nature
; 614(7948): 539-547, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725933
2.
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Immunity
; 49(5): 958-970.e7, 2018 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446386
3.
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
J Immunol
; 201(4): 1211-1221, 2018 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29997125
4.
Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB.
J Immunol
; 200(5): 1937-1950, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29351998
5.
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.
J Immunol
; 198(10): 3999-4011, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28404636
6.
Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.
Blood
; 125(1): 102-10, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25395427
7.
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.
J Immunol
; 195(11): 5503-16, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26512139
8.
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
J Immunol
; 193(4): 1828-35, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25024386
9.
Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Eur J Immunol
; 42(8): 2109-20, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22760702
10.
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
Cancer Immunol Immunother
; 62(5): 941-8, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23543215
11.
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
Blood
; 118(9): 2530-40, 2011 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21768293
12.
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
J Immunol
; 187(4): 1754-63, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21742972
13.
Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc.
Front Immunol
; 14: 1252274, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37965342
14.
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Blood
; 115(25): 5191-201, 2010 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20223920
15.
Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35017153
16.
Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.
Commun Biol
; 5(1): 229, 2022 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288635
17.
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Cell Rep
; 40(3): 111099, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35858562
18.
TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.
Commun Biol
; 4(1): 772, 2021 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162985
19.
FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion.
J Immunother Cancer
; 8(1)2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32554613
20.
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Cancer Cell
; 37(6): 850-866.e7, 2020 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442402